Pharmaceutical Technology on MSN

Gilead Sciences to acquire Repare’s RP-3467

Gilead will pay Repare $25m upfront, and up to an additional $5m upon completion of certain technology transfer activities.
Baylor College of Medicine

TFEB and V-ATPase-mediated Lysosomal Stress Sensing Pathway in Tauopathy

Early work revealed that TFEB is highly effective in ameliorating tau/NFT pathology and rescuing cognitive impairment and neurodegeneration. TFEB targets only the aberrant tau species and this ...
JSTOR Daily

Properties of the Peribacteroid Membrane ATPase of Pea Root Nodules and Its Effect on the Nitrogenase Activity

Peribacteroid membrane vesicles from pea (Pisum sativum) root nodules were isolated from membrane-enclosed bacteroids by an osmotic shock. The ATPase activity associated with this membrane preparation ...
Business Wire

Repare Therapeutics Doses First Patient in Phase 1 Clinical Trial of RP-3467, a Polθ ATPase Inhibitor

CAMBRIDGE, Mass. & MONTREAL--(BUSINESS WIRE)--Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a leading clinical-stage precision oncology company, today announced the first ...

Repare Therapeutics Announces Acquisition of Polθ ATPase Inhibitor, RP-3467, by Gilead Sciences for Up To $30 Million in Total Consideration

Repare Therapeutics Inc. ("Repare" or the "Company") (Nasdaq: RPTX), a clinical-stage precision oncology company, today announced a definitive asset purchase agreement for Gilead Sciences, Inc. to ...
Morningstar

Repare Therapeutics Announces Acquisition of Polθ ATPase Inhibitor, RP-3467, by Gilead Sciences for Up To $30 Million in Total Consideration

Repare Therapeutics Announces Acquisition of Polθ ATPase Inhibitor, RP-3467, by Gilead Sciences for Up To $30 Million in Total Consideration Repare Therapeutics Inc. (“Repare” or the “Company”) ...